MISSISSAUGA, Ontario--(BUSINESS WIRE)--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, announced today that it will be showcasing its full portfolio of Advanced Wound Management and Infection Prevention products at the Limb Salvage and Woundcare Symposium in Cleveland, Ohio on October 6th and 7th, 2017.
The Company’s CovaWound™, ColActive®, and MediClear™ PreOp brands have strong evidence to support their efficacy in killing the bacteria most commonly associated with infections in surgical procedures and chronic diabetic foot wounds. When used together, ColActive and CovaWound help to promote rapid closure of chronic wounds.
“This will be Covalon’s first time exhibiting at the Limb Salvage and Woundcare Symposium”, said John R. Hands, Executive Vice President. “Our range of products are a perfect fit for this group of professionals that include some of the US’s leading Internists, Vascular Surgeons, Podiatrists, Wound and Acute Care Specialists.”
The increasing incidence of diabetic foot ulcers and wounds creates challenges for practitioners regarding strategies to treat this complex comorbidity. As a result, practitioners are constantly looking to stay abreast of the most recent advances and techniques to help those patients not responding to other less advanced medical products. Covalon’s CovaWound and ColActive Plus product lines provide clinicians with the advanced technologies needed to help chronic wound patients to heal.
This year's program brings together the most renowned lower limb specialists to discuss the latest education and outcomes needed to heal wounds and prevent amputations. To learn more about Covalon’s line of products, visit booth 10 during exhibit hours, or email [email protected]
About Covalon
Covalon Technologies Ltd. researches, develops
and commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and services
address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies
are used to prevent, detect and manage medical conditions in specialty
areas such as wound care, tissue repair, infection control, disease
management, medical device coatings and biocompatibility. To learn more
about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171005005137/en/
